CNS Disorders  >>  Lybalvi (olanzapine/samidorphan)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lybalvi (olanzapine/samidorphan) / Alkermes
NCT01903837 / 2013-002193-45: A Study of ALKS 3831 in Adults With Schizophrenia

Checkmark In schizophrenia
Sep 2016 - Sep 2016: In schizophrenia
Completed
2
347
Europe, US, RoW
Samidorphan (Low Dose), Low dose samidorphan (ALKS 33), Samidorphan (Medium Dose), Medium dose samidorphan (ALKS 33), Samidorphan (High Dose), High dose samidorphan (ALKS 33), Placebo, Olanzapine
Alkermes, Inc.
Schizophrenia
12/14
03/15
NCT02161718 / 2014-001211-39: A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

Completed
2
300
Europe, US
Samidorphan + olanzapine (ALKS 3831), Placebo + olanzapine
Alkermes, Inc.
Schizophrenia, Alcohol Use Disorder
01/17
02/17

Download Options